Bayer exploring sale of dermatology business: Bloomberg

September 8, 2016 1:31 PM EDT

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

(Reuters) - German chemicals and crop pesticides firm Bayer AG is exploring the sale of its dermatology business to push forward its deal with Monsanto Co (NYSE: MON), Bloomberg reported, citing sources.

Bayer is working with JPMorgan Chase & Co (NYSE: JPM) on the sale, which could fetch more than 1 billion euros ($1.12 billion), the report said. (http://bloom.bg/2cGiTXB)

Bayer said on Monday it was willing to offer more than $65 billion, a 2 percent increase on its previous offer for the world's largest seeds company Monsanto.

The dermatology business could attract interest from existing makers of skincare products including Nestle SA's Galderma, Allergan Plc (NYSE: AGN) and Almirall SA (NYSE: ALM), as well as private equity firms, according to the Bloomberg report.

Bayer and J.P. Morgan were not immediately available for comment.

(Reporting by Aishwarya Venugopal in Bengaluru; Editing by Shounak Dasgupta)



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Reuters

Related Entities

JPMorgan

Add Your Comment